Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure–activity relationships, and therapeutic perspectives

Post time 27 min. ago

journal：European Journal of Medicinal Chemistry

Authors：Eman M. Elkafoury; Tarek F. El-Moselhy; Mervat H. El-Hamamsy; Eman A. El-Bastawissy; Esraa Y. Rabea; Kamyar Afarinkia; Peter A. Sidhom

Published date：2026-10-

DOI：10.1016/j.ejmech.2026.119047

PDF link：https://www.sciencedirect.com/sc ... 223523426004927/pdf

Article link：https://doi.org/10.1016/j.ejmech.2026.119047

Article Source：Elsevier BV。

Remark：

Post time 34 s. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

Post time 2 s. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Elsevier] Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure–activity relationships, and therapeutic perspectives

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure–activity relationships, and therapeutic perspectives Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure–activity relationships, and therapeutic perspectives